RecruitingPhase 1NCT02455479

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals

Phase I Randomized, Double-blind, Placebo Control Study for an Anti-cocaine Vaccine

Sponsor

Weill Medical College of Cornell University

Enrollment

150 participants

Start Date

Sep 13, 2016

Study Type

INTERVENTIONAL

Conditions

Cocaine Dependence

Summary

The purpose of this study is to assess the safety and preliminary efficacy of an anti-cocaine vaccine called dAd5GNE in cocaine-dependent individuals. It uses the concept of a vaccine to treat the neurological effects of cocaine by evoking "immunity" to prevent the effects of cocaine on the brain.

Eligibility

Min Age: 21 YearsMax Age: 69 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Placebo and a biological treatment called dAd5GNE Vaccine for people with cocaine dependence. The study is currently recruiting participants at 1 location. People eligible for this study include aged 21 Years to 69 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.